Monitoring and Management of MZ Alpha-1 Antitrypsin Phenotype

Introduction to MZ Phenotype

The American Thoracic Society recommends that individuals with the MZ alpha-1 antitrypsin phenotype do not require routine specialized monitoring unless they have risk factors such as smoking, occupational exposures, or abnormal liver function tests 1, 2
The MZ phenotype is an intermediate alpha-1 antitrypsin (AAT) deficiency state where one normal M allele and one deficient Z allele are inherited in a codominant fashion, resulting in AAT plasma levels around 60% of normal 1
This phenotype is considered a predisposition rather than a disease itself, with potential risk for developing lung or liver disease under certain conditions 1

The American College of Chest Physicians states that MZ individuals have a slightly increased risk of developing COPD compared to the general population, with a relative risk of 2.2 for hospitalization due to COPD 3
Risk factors that significantly increase the likelihood of developing lung disease in MZ individuals include cigarette smoking, occupational exposure to dust, gases, or fumes, and family history of COPD 4

The American Association for the Study of Liver Diseases estimates that the risk of developing cirrhosis for MZ individuals between ages 18-50 is estimated at 2-5% 5
The risk of liver disease may increase with age, particularly in never-smokers over 50 years 5
Liver disease in AAT deficiency can occur at any age, with peak incidence in elderly never-smokers 6

The American Thoracic Society recommends confirming the MZ phenotype through qualitative testing if not already done, and performing baseline pulmonary function tests (PFTs) and liver function tests 7, 6
For asymptomatic MZ individuals without risk factors, clinical evaluation every 1-2 years, liver function tests every 1-2 years, and pulmonary function tests every 3-5 years are recommended 8, 6
For MZ individuals with risk factors, more frequent clinical evaluations, annual pulmonary function tests, and annual liver function tests are recommended 8, 6

The American College of Chest Physicians recommends smoking cessation as the single most important intervention, as well as avoidance of environmental irritants and occupational exposures, maintaining up-to-date vaccination status, and encouraging regular exercise, healthy diet, and pulmonary hygiene 8, 9

The American Thoracic Society suggests considering testing first-degree relatives for AAT deficiency and genetic counseling, especially if planning future pregnancies 7

The American College of Chest Physicians recommends pulmonology referral if abnormal pulmonary function tests, respiratory symptoms develop, or FEV1 decline greater than expected for age 8, 7
Hepatology referral is recommended if abnormal liver function tests persist or signs or symptoms of liver disease develop 6

Individuals with MZ phenotype have significantly reduced AAT levels compared to normal MM individuals, with a mean difference of approximately 52 mg/dL lower 10

The American Thoracic Society notes that MZ smokers show odds ratios of 2.8 for rapid FEV1 decline 11
The combination of MZ genotype with family history of COPD increases risk substantially, with an odds ratio of 9.7 11
Environmental and occupational exposures further increase susceptibility to obstructive lung disease in MZ individuals 11

Multiple studies demonstrate increased risk for chronic liver disease in MZ heterozygotes, with odds ratios ranging from 1.8 to 3.1 12, 13
Cryptogenic cirrhosis shows particular overrepresentation of MZ phenotype, with prevalence of 20.5-21% in cryptogenic cases compared to only 2.6-3.5% in other cirrhosis types 12, 13
Hepatitis C infection may act as an additive risk factor for liver disease in MZ individuals 12
No association exists between MZ phenotype and autoimmune liver disease or hepatitis B-related cirrhosis 12, 13